• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Nkarta Inc. (Amendment)

    4/5/24 12:21:59 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NKTX alert in real time by email
    SC 13G/A 1 us65487u1088_040424.txt us65487u1088_040424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) Nkarta, Inc. -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 65487U108 -------------------------------------------------------- (CUSIP Number) March 31, 2024 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 65487U108 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 2732064 (6) Shared voting power 0 (7) Sole dispositive power 2825506 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 2825506 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 4.0% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- Nkarta, Inc. Item 1(b) Address of issuer's principal executive offices: ----------------------------------------------------------------------- 1150 VETERANS BOULEVARD SOUTH SAN FRANCISCO CA 94080 Item 2. 2(a) Name of person filing: ---------------------------------------------------------------------- BlackRock, Inc. 2(b) Address or principal business office or, if none, residence: ----------------------------------------------------------------------- BlackRock, Inc. 50 Hudson Yards New York, NY 10001 2(c) Citizenship: -------------------------------------------------------------------- See Item 4 of Cover Page 2(d) Title of class of securities: ------------------------------------------------------------------- Common Stock 2(e) CUSIP No.: See Cover Page Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: [ ] Broker or dealer registered under Section 15 of the Act; [ ] Bank as defined in Section 3(a)(6) of the Act; [ ] Insurance company as defined in Section 3(a)(19) of the Act; [ ] Investment company registered under Section 8 of the Investment Company Act of 1940; [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; [ ] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. Amount beneficially owned: 2825506 Percent of class 4.0% Number of shares as to which such person has: Sole power to vote or to direct the vote 2732064 Shared power to vote or to direct the vote 0 Sole power to dispose or to direct the disposition of 2825506 Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ X ]. Item 6. Ownership of More than 5 Percent on Behalf of Another Person [ N/A ] Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. See Exhibit A Item 8. Identification and Classification of Members of the Group If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. Item 9. Notice of Dissolution of Group Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: April 4, 2024 BlackRock, Inc. Signature: Spencer Fleming ------------------------------------------- Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit A Subsidiary Aperio Group, LLC BlackRock Advisors, LLC BlackRock Asset Management Canada Limited BlackRock Fund Advisors BlackRock Institutional Trust Company, National Association BlackRock Financial Management, Inc. BlackRock Investment Management, LLC *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Exhibit B POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Daniel Goldmintz, Laura Hildner, Elizabeth Kogut, David Maryles, Christopher Meade, Una Neary, Charles Park, Daniel Riemer, David Rothenberg and Brenda Schulz, acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing, in its name and on its behalf and on behalf of its direct and indirect subsidiaries, any and all documents, certificates, instruments, statements, filings, agreements and amendments (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Schedules 13D and 13G and Forms 3, 4, 5, 13F and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental or regulatory authority or other person, and giving and granting to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as the Company and/or its direct and indirect subsidiaries, as applicable, might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall expressly revoke the power of attorney dated 2nd day of January, 2019 in respect of the subject matter hereof, shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 30th day of April, 2023. BlackRock, Inc. By: /s/ R. Andrew Dickson, III Name: R. Andrew Dickson, III Title: Corporate Secretary
    Get the next $NKTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NKTX

    DatePrice TargetRatingAnalyst
    10/9/2024$14.00Buy
    Rodman & Renshaw
    8/14/2024$16.00Outperform → Strong Buy
    Raymond James
    3/22/2024$13.00 → $16.00Strong Buy → Outperform
    Raymond James
    12/22/2022Outperform → Perform
    Oppenheimer
    10/10/2022$25.00Buy
    Canaccord Genuity
    7/28/2022$26.00Buy
    Needham
    7/18/2022$30.00Outperform
    SVB Leerink
    3/11/2022$17.00Outperform
    Raymond James
    More analyst ratings

    $NKTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nkarta to Participate in an April Investor Conference

      SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 24th Annual Needham Virtual Healthcare ConferenceApril 8, 202511:00 a.m. ET – fireside chat   A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmu

      4/1/25 8:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

      Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune indications expected in second half of 2025Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestonesCash balance of $380.5 million on December 31, 2024, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWI

      3/26/25 4:01:00 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta to Participate in March Investor Conferences

      SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences: TD Cowen 45th Annual Health Care ConferenceMarch 3, 20253:10 p.m. ET – fireside chat Leerink Partners 2025 Global Healthcare ConferenceMarch 10, 20253:00 p.m. ET – fireside chat A simultaneous webcast of the events will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the

      2/25/25 8:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nkarta Inc.

      SC 13G - Nkarta, Inc. (0001787400) (Subject)

      12/13/24 5:02:47 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

      SC 13G/A - Nkarta, Inc. (0001787400) (Subject)

      11/14/24 4:05:12 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

      SC 13G/A - Nkarta, Inc. (0001787400) (Subject)

      11/14/24 8:55:31 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Shook David sold $19,004 worth of shares (8,638 units at $2.20), decreasing direct ownership by 4% to 190,955 units (SEC Form 4)

      4 - Nkarta, Inc. (0001787400) (Issuer)

      1/17/25 5:37:19 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Levin Alyssa sold $12,844 worth of shares (5,838 units at $2.20), decreasing direct ownership by 5% to 102,662 units (SEC Form 4)

      4 - Nkarta, Inc. (0001787400) (Issuer)

      1/17/25 5:36:57 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Technical Officer Brandenberger Ralph sold $16,383 worth of shares (7,447 units at $2.20), decreasing direct ownership by 6% to 124,796 units (SEC Form 4)

      4 - Nkarta, Inc. (0001787400) (Issuer)

      1/17/25 5:36:35 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Nkarta Inc.

      DEFA14A - Nkarta, Inc. (0001787400) (Filer)

      4/21/25 4:20:22 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Nkarta Inc.

      DEF 14A - Nkarta, Inc. (0001787400) (Filer)

      4/21/25 4:19:22 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Nkarta Inc.

      10-K - Nkarta, Inc. (0001787400) (Filer)

      3/26/25 4:20:11 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Nkarta with a new price target

      Rodman & Renshaw initiated coverage of Nkarta with a rating of Buy and set a new price target of $14.00

      10/9/24 7:55:21 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta upgraded by Raymond James with a new price target

      Raymond James upgraded Nkarta from Outperform to Strong Buy and set a new price target of $16.00

      8/14/24 7:45:34 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta downgraded by Raymond James with a new price target

      Raymond James downgraded Nkarta from Strong Buy to Outperform and set a new price target of $16.00 from $13.00 previously

      3/22/24 7:49:46 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    Financials

    Live finance-specific insights

    See more
    • Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

      New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B cells, could modify refractory autoimmune disease while maintaining NK-driven safety profile Off-the-shelf accessibility and proprietary engineering could eliminate burdens of autologous products and may enable differentiating conditioning regimen Resource prioritization and cost reductions expected to extend cash runway by one year into 2026 to support important clinical data readouts in 2024 Estimated cash and cash equivalents of $278.4 mil

      10/17/23 7:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

      SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, October 17, 2023 at 8:00 a.m. ET to discuss clinical program updates and organizational cost measures and resource prioritization to support clinical milestones. Conference Call and WebcastTo access the conference call, please register through this link: https://nkarta-business-update.open-exchange.net/registration A replay will be archived on the Investors section of Nkarta's website, www.nkartatx.com, for approximately four weeks. About NkartaNkart

      10/16/23 4:01:00 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

      Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating Ara-C (cytarabine)In patients with r/r AML treated with a three-dose regimen of NKX101 at 1.5 billion cells per dose after fludarabine/Ara-C for lymphodepletion, n=6 4 of 6 patients achieved complete response (67% CR/CRi, 50% CR rate)2 CRs with MRD negativity1 patient deepened response to MRD negative CRi with additional cycles NKX101 was well tolerated across dose-levels and lymphodepletion regimensExpansion cohort incorporating Ara-C based lymphodepletion expected to be the basis of NKX101 development moving forwardUpdated clinic

      6/27/23 7:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ra Capital Management, L.P. bought $30,000,000 worth of shares (3,000,000 units at $10.00) (SEC Form 4)

      4 - Nkarta, Inc. (0001787400) (Issuer)

      3/29/24 5:38:04 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • George Simeon bought $20,000,000 worth of shares (2,000,000 units at $10.00) (SEC Form 4)

      4 - Nkarta, Inc. (0001787400) (Issuer)

      3/28/24 4:30:06 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

      SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings. "This new leadership structure enables Nkarta to meet this transformative moment for cell therapy as

      7/16/24 6:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

      5/15/24 4:05:00 PM ET
      $ENGN
      $NAMS
      $NKTX
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

      NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimenNKX019 clinical data presented at EHA 2023 and ICML 2023 meetingsClinical updates planned for NKX019 in the second half of 2023 and NKX101 in the first half of 2024Cash and cash equivalents of $302.2 million on June 30, 2023; cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2

      8/10/23 7:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care